Biodesix Stock Based Compensation from 2010 to 2024

BDSX Stock

USD 1.44 0.01 0.70%

Biodesix Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation will likely drop to about 3.7 M in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2018-03-31

Previous Quarter

1.2 M

Current Value

1.5 M

Quarterly Volatility

937.2 K

Covid

Check Biodesix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biodesix's main balance sheet or income statement drivers, such as Interest Income of 25.9 K, Depreciation And Amortization of 3.2 M or Interest Expense of 6.5 M, as well as many indicators such as Price To Sales Ratio of 2.92, Dividend Yield of 0.0 or PTB Ratio of 34.64. Biodesix financial statements analysis is a perfect complement when working with Biodesix Valuation or Volatility modules.

Check out the analysis of Biodesix Correlation against competitors.

For more information on how to buy Biodesix Stock please use our How to Invest in Biodesix guide.

Latest Biodesix's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Biodesix over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Biodesix's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biodesix's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Biodesix Stock Based Compensation Regression Statistics

	Arithmetic Mean	1,677,099
	Geometric Mean	459,948
	Coefficient Of Variation	137.52
	Mean Deviation	2,043,065
	Median	142,000
	Standard Deviation	2,306,394
	Sample Variance	5.3T
	Range	5.8M
	R-Value	0.80
	Mean Square Error	2.1T
	R-Squared	0.64
	Significance	0.0003
	Slope	412,509
	Total Sum of Squares	74.5T

Biodesix Stock Based Compensation History

	2024	3.7 M
	2023	5.4 M
	2022	6 M
	2021	4.9 M
	2020	3.7 M
	2019	170 K

Other Fundumenentals of Biodesix

Stock Based Compensation To Revenue

Biodesix Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt	Short Term Debt	Deferred Long Term Liab
Total Assets		0.96	0.96	0.61	-0.49	-0.77	0.82	-0.05	0.88	0.93	-0.92	0.97	0.97	0.78	0.75	-0.85	0.78	0.75	-0.68	-0.67	-0.43
Total Stockholder Equity	0.96		1.0	0.51	-0.51	-0.83	0.66	-0.15	0.74	0.95	-0.99	1.0	0.92	0.82	0.68	-0.9	0.82	0.8	-0.82	-0.81	-0.47
Net Tangible Assets	0.96	1.0		0.48	-0.47	-0.85	0.65	-0.11	0.73	0.96	-0.99	1.0	0.91	0.85	0.65	-0.91	0.85	0.82	-0.84	-0.83	-0.51
Current Deferred Revenue	0.61	0.51	0.48		-0.82	-0.05	0.82	-0.63	0.76	0.39	-0.5	0.5	0.75	0.01	0.78	-0.21	0.01	-0.02	-0.02	-0.03	0.24
Net Debt	-0.49	-0.51	-0.47	-0.82		-0.03	-0.52	0.73	-0.44	-0.29	0.55	-0.47	-0.65	0.03	-0.84	0.14	0.03	0.07	0.12	0.09	-0.44
Retained Earnings	-0.77	-0.83	-0.85	-0.05	-0.03		-0.36	-0.29	-0.52	-0.91	0.8	-0.85	-0.64	-0.99	-0.23	0.97	-0.99	-0.99	0.93	0.92	0.79
Accounts Payable	0.82	0.66	0.65	0.82	-0.52	-0.36		-0.22	0.97	0.6	-0.6	0.68	0.87	0.37	0.79	-0.44	0.37	0.32	-0.16	-0.17	-0.23
Long Term Debt	-0.05	-0.15	-0.11	-0.63	0.73	-0.29	-0.22		-0.09	0.08	0.19	-0.11	-0.26	0.35	-0.38	-0.2	0.35	0.37	-0.09	-0.07	-0.38
Net Receivables	0.88	0.74	0.73	0.76	-0.44	-0.52	0.97	-0.09		0.72	-0.67	0.76	0.9	0.52	0.72	-0.6	0.52	0.48	-0.32	-0.32	-0.33
Good Will	0.93	0.95	0.96	0.39	-0.29	-0.91	0.6	0.08	0.72		-0.93	0.96	0.83	0.89	0.49	-0.97	0.89	0.88	-0.86	-0.87	-0.56
Total Liab	-0.92	-0.99	-0.99	-0.5	0.55	0.8	-0.6	0.19	-0.67	-0.93		-0.98	-0.89	-0.8	-0.67	0.88	-0.8	-0.77	0.84	0.83	0.41
Net Invested Capital	0.97	1.0	1.0	0.5	-0.47	-0.85	0.68	-0.11	0.76	0.96	-0.98		0.93	0.85	0.67	-0.91	0.85	0.82	-0.82	-0.82	-0.51
Total Current Assets	0.97	0.92	0.91	0.75	-0.65	-0.64	0.87	-0.26	0.9	0.83	-0.89	0.93		0.64	0.85	-0.73	0.64	0.61	-0.56	-0.55	-0.3
Capital Stock	0.78	0.82	0.85	0.01	0.03	-0.99	0.37	0.35	0.52	0.89	-0.8	0.85	0.64		0.28	-0.95	1.0	1.0	-0.9	-0.89	-0.79
Net Working Capital	0.75	0.68	0.65	0.78	-0.84	-0.23	0.79	-0.38	0.72	0.49	-0.67	0.67	0.85	0.28		-0.35	0.28	0.22	-0.2	-0.16	0.1
Intangible Assets	-0.85	-0.9	-0.91	-0.21	0.14	0.97	-0.44	-0.2	-0.6	-0.97	0.88	-0.91	-0.73	-0.95	-0.35		-0.95	-0.95	0.93	0.92	0.63
Common Stock	0.78	0.82	0.85	0.01	0.03	-0.99	0.37	0.35	0.52	0.89	-0.8	0.85	0.64	1.0	0.28	-0.95		1.0	-0.9	-0.89	-0.79
Property Plant Equipment	0.75	0.8	0.82	-0.02	0.07	-0.99	0.32	0.37	0.48	0.88	-0.77	0.82	0.61	1.0	0.22	-0.95	1.0		-0.91	-0.89	-0.78
Short Long Term Debt	-0.68	-0.82	-0.84	-0.02	0.12	0.93	-0.16	-0.09	-0.32	-0.86	0.84	-0.82	-0.56	-0.9	-0.2	0.93	-0.9	-0.91		0.99	0.61
Short Term Debt	-0.67	-0.81	-0.83	-0.03	0.09	0.92	-0.17	-0.07	-0.32	-0.87	0.83	-0.82	-0.55	-0.89	-0.16	0.92	-0.89	-0.89	0.99		0.65
Deferred Long Term Liab	-0.43	-0.47	-0.51	0.24	-0.44	0.79	-0.23	-0.38	-0.33	-0.56	0.41	-0.51	-0.3	-0.79	0.1	0.63	-0.79	-0.78	0.61	0.65

Click cells to compare fundamentals

About Biodesix Financial Statements

Biodesix investors use historical fundamental indicators, such as Biodesix's Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biodesix. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	5.4 M	3.7 M
Stock Based Compensation To Revenue	0.11	0.06

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Biodesix Stock Analysis

When running Biodesix's price analysis, check to measure Biodesix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodesix is operating at the current time. Most of Biodesix's value examination focuses on studying past and present price action to predict the probability of Biodesix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodesix's price. Additionally, you may evaluate how the addition of Biodesix to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biodesix Stock Based Compensation from 2010 to 2024

Latest Biodesix's Stock Based Compensation Growth Pattern

Biodesix Stock Based Compensation Regression Statistics

Biodesix Stock Based Compensation History

Other Fundumenentals of Biodesix

Biodesix Stock Based Compensation component correlations

About Biodesix Financial Statements

Also Currently Popular

Additional Tools for Biodesix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY